Treatment of hypercholesterolaemia with PCSK-9 Inhibitors in Denmark. Assessment of real-life data; safety an extent of adverse effects after the first years of clinical use.

31 August 2019 (00:00 - 00:00)

Organised by:

Sign in to view the resources

About the speaker

Doctor Stefan Mulverstedt

Bispebjerg University Hospital, Copenhagen (Denmark)

8 More presentations in this session

Presentation thumbnail

The KCa2 channel inhibitor AP14145, but not dofetilide or ondansetron, provides functional atrial selectivity in guinea pig hearts

Associate Professor N. Edvardsson (Gothenburg, SE)

Abstract Slides

Presentation thumbnail

Mechanisms of action of the small conductance Ca2+-activated K+-channel modulator AP30663, a novel compound being developed for treatment of atrial fibrillation in man

Mrs S. Bomholtz (Copenhagen N, DK)

Abstract Slides

Presentation thumbnail

The SK channel inhibitor AP30663, converts vernakalant-resistant persistent AF and prevents its reinduction in pigs

Doctor J. Diness (Frederiksberg, DK)

Presentation thumbnail

The role of a phosphoinositide-3 kinase inhibitor in vascular inflammation

Miss H. Chaudhry (London, GB)

Abstract Slides

Presentation thumbnail

Anti-thrombin nanoparticles for reduce vascular damage and promote functional recovery in acute ischemic kidney injury well after reperfusion

Associate Professor H. Pan (Saint Louis, US)

Access the full session

Session thumbnail

Poster Session 1 - Preclinical pharmacotherapy

The Event

ESC Congress 2019

31 August - 4 September 2019

You may be interested in

Congress Presentation

Lipid control in cardiovascular patients

Congress Presentation

What’s new in LDL lowering?

Congress Presentation

Stepwise approach to lipid-lowering therapies: which one, when, and for whom?

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources